Brief: Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan
12/01/2026 12:35
Jan 12 (Reuters) - Nuvation Bio Inc NUVB.N: NUVATION BIO AND EISAI ENTER INTO EXCLUSIVE LICENSING AGREEMENT FOR TALETRECTINIB IN EUROPE AND ADDITIONAL COUNTRIES OUTSIDE U.S., CHINA AND JAPAN NUVATION BIO INC - TO RECEIVE UP TO €195 MILLION IN PAYMENTS NUVATION BIO INC - EISAI RECEIVES EXCLUSIVE RIGHTS FOR TALETRECTINIB IN MULTIPLE REGIONS NUVATION BIO INC: MAA FOR TREATMENT OF ADVANCED ROS1+ NSCLC IS EXPECTED TO BE FILED IN EUROPE IN FIRST HALF OF 2026 NUVATION BIO INC - MAA FOR TALETRECTINIB EXPECTED IN EUROPE IN 2026 Source text: ID:nBw7jpqCqa Further company coverage: NUVB.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China